Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D3SPE5
|
|||
| Drug Name |
BAY 1905254
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Bayer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ig-like domain-containing receptor 2 (ILDR2) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03666273) A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254. U.S. National Institutes of Health. | |||
| REF 2 | Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). Cancer Immunol Res. 2020 Jul;8(7):895-911. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.